Clinical trials: Hepatocellular Cancer
Refractory Hepatocellular Carcinoma
JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment Failure
The goal of this clinical trial is to evaluate the safety and efficacy of JDB153 combined with Penpulimab in patients with hepatocellular carcinoma after standard treatment failure.
- Trial name
- NCT07075419
- Testing
- JDB153, Penpulimab
- Volunteers
- 10 people
- Sponsor
- West China Hospital
Hepatocellular Carcinoma (HCC)
TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion
This is a prospective, randomized study designed to compare the efficacy of transcatheter hepatic artery chemoembolization (TACE) combined with bevacizumab arterial perfusion versus conventional therapy in patients with…
- Trial name
- NCT07075562
- Testing
- Bevacizumab Arterial Perfusion plus TACE, Conventional Therapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- The First Hospital of Hebei Medical University
Hepatocellular Carcinoma
Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy.
Hepatocellular carcinoma is prone to invade the portal vein and form portal vein thrombosis, and patients in this period are directly included in the advanced stages, i.e. Barcelona clinical liver cancer stage C.
- Trial name
- NCT06248528
- Testing
- Liver resection, Locoregional therapy
- Where
- China
- Volunteers
- 1,076 people
- Sponsor
- Chen Xiaoping
Carcinoma, Hepatocellular, Liver Neoplasms
RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System
Hepatocellular carcinoma (HCC) is the 9th leading cause of cancer-related death in the US and one of the leading causes of death in patients with cirrhosis.
- Trial name
- NCT02312817
- Testing
- Mailed Outreach Invitation, Mailed Outreach Invitation and Patient Navigation
- Where
- United States
- Volunteers
- 1,800 people
- Sponsor
- University of Texas Southwestern Medical Center
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
This will be a Phase II study investigating single agent pembrolizumab (Keytruda®) as a second-line therapy for subjects with hepatocellular carcinoma (HCC) who either progressed on or after sorafenib or did not tolerate…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection, Refractory Liver Carcinoma
- Trial name
- NCT02940496
- Testing
- Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study
This is a clinical trial that aims to evaluate whether adding a bile acid called tauroursodeoxycholic acid (TUDCA) can improve the effects of immunotherapy in patients with advanced liver cancer (hepatocellular carcinoma).
- Trial name
- NCT07064668
- Testing
- TUDCA (Tauroursodeoxycholic Acid) Supplementation, Immune checkpoint inhibitor (ICI)
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
This is an observational study. All patients who meet the inclusion criteria of our previous Phase 2, open-label, single-arm study of neoadjuvant immune-checkpoint blockade therapy (AK104) combining with TACE for resectable…
- Trial name
- MORNING-RWS (NCT07064681)
- Testing
- Surgery with and without the aid of Indocyanine Green (ICG)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Transcatheter Arterial Chemoembolization, Unresectable Hepatocellular Carcinoma
A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellularcarcinoma Undergoing Transcatheter Arterial Chemoembolization in Combination With Immunotherapy and Targeted Therapy
The entry point of this study is the proposition of "generative longitudinal prediction," which utilizes only pre-treatment imaging to create high-fidelity predictions of post-treatment imaging.
- Trial name
- NCT07065786
- Testing
- Generative model
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Zhongda Hospital
Melanoma, Breast Cancer
Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors
This study evaluates whether it is safe to Focused Ultrasound Ablation (FUSA) treatments with and without PD-1 blockade and with and without intratumoral poly-ICLC. A device called the Echopulse will be used for the FUSA therapy.
- Conditions
- Melanoma, Breast Cancer, Merkel Cell Carcinoma, Squamous Cell Cancer
- Trial name
- AM-003 (NCT04116320)
- Testing
- Echopulse, Poly ICLC, Standard of Care PD-1 Therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Craig L Slingluff, Jr
Advanced Solid Tumor, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB099280 in participants with select solid tumors
- Conditions
- Advanced Solid Tumor, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04242199
- Testing
- INCB099280
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 182 people
- Sponsor
- Incyte Corporation
Liver Tumors
Safety and Clinical Efficacy of Histotripsy for Liver Cancers Adjacent to Major Intrahepatic Vessels
Malignant liver tumors are among the most common malignancies worldwide, with over 10,000 new cases diagnosed annually in Taiwan.
- Trial name
- NCT07063771
- Testing
- Histotripsy
- Volunteers
- 20 people
- Sponsor
- National Taiwan University Hospital
Ovarian Cancer, Bladder Cancer
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as…
- Conditions
- Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04580485
- Testing
- INCB106385, INCMGA00012
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 54 people
- Sponsor
- Incyte Corporation
Cervical Cancer, Colorectal Cancer
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
- Conditions
- Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- STARBURST (NCT05563272)
- Testing
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Liver Cancer and Immunotherapy in the Liquid Biopsy Era
The goal of this prospective clinical trial is to identify a predictive biomarker in patients with advanced HCC (stage B and C) using a combinatorial approach of the liquid biopsy.
- Conditions
- Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Immune Checkpoint Inhibitor
- Trial name
- LILIPSY (NCT05810402)
- Testing
- Liquid Biopsy
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
HCC - Hepatocellular Carcinoma
Downstaging Prediction Model for HCC
This study is a real-world, single-center study that collects imaging and clinical data from patients with HCC who are downstaged beyond the UCSF criteria.
- Trial name
- NCT07058649
- Volunteers
- 369 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical Trial
This clinical trial aims to systematically evaluate the clinical performance and accuracy of the HepaAiQ test kit, a multi-gene methylation assay based on PCR with fluorescent probe detection.
- Trial name
- NCT06842563
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Singlera Genomics Inc.
Hepatocellular Carcinoma (HCC)
TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma
This study investigates the clinical efficacy and safety of transarterial chemoembolization (TACE) combined with the immune agent nivolumab compared to TACE alone for treating hepatocellular carcinoma (HCC).
- Trial name
- NCT07053202
- Testing
- Nivolumab, Transarterial Chemoembolization (TACE)
- Where
- China
- Volunteers
- 140 people
- Sponsor
- The First Hospital of Hebei Medical University
Liver Cancer, Adult
The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/Contrast-enhanced MRI in Malignant Liver Lesions
Liver disease, a major global health burden, ranges from mild dysfunction to severe conditions like cirrhosis and hepatocellular carcinoma (HCC), the fifth most common cancer.
- Trial name
- NCT07055048
- Volunteers
- 60 people
- Sponsor
- Shanghai East Hospital
Advanced Hepatocellular Carcinoma
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic…
- Trial name
- NCT05797805
- Testing
- Tegavivint, Lenvatinib, Cabozantinib
- Where
- 8 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- Iterion Therapeutics
Hepatocellular Carcinoma
The Efficacy of Sequential RT After Triple Therapy for uHCC
Triple therapy of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies has demonstrated excellent efficacy in unresectable hepatocellular carcinoma (uHCC).
- Trial name
- NCT07052448
- Testing
- sequential radiotherapy after the combination of transcatheter arterial chemoembolization (TACE) combined with lenvatinib and anti-PD-1 antibodies
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Fujian Provincial Hospital